Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Explore linked clinical trials.287 results · Page 1 of 12
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid Tumors | childhood malignant neoplasm, neoplasm | Not yet recruiting | Not applicable | 2026-10-08 | NCT07866534 | |
| Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC | Advanced Hepatocellular Carcinoma (HCC) | Not yet recruiting | Phase 2 | 2026-10-08 | NCT07847671 | |
| Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. | Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Not yet recruiting | Phase 2 | 2026-10-02 | NCT07854977 | |
| FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Not yet recruiting | Phase 2 | 2026-10-01 | NCT07845565 | |
| Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-10-01 | NCT07318831 | |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-09-28 | NCT07372079 | |
| Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Not stated | 2026-09-24 | NCT07840092 | |
| Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy | Gastrectomy; Postoperative Analgesia | Recruiting | Phase 2 | 2026-09-22 | NCT07330063 | |
| Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Not applicable | 2026-09-21 | NCT07831889 | |
| Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2026-09-18 | NCT07828756 | |
| Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic Hepatectomy | Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agnosia, nervous system disorder, perceptual disorders | Not yet recruiting | Phase 2 | 2026-09-17 | NCT07826806 | |
| Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer | cancer, neoplasm | Recruiting | Phase 2 | 2026-09-17 | NCT06495515 | |
| Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anxiety, anxiety disorder, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, psychiatric disorder | Not yet recruiting | Not applicable | 2026-09-16 | NCT07796906 | |
| Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-09-16 | NCT07763587 | |
| Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Not applicable | 2026-09-15 | NCT06146946 | |
| SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, histiocytoma, neoplasm, sarcoma, undifferentiated pleomorphic sarcoma | Not yet recruiting | Phase 2 | 2026-09-14 | NCT07817095 | |
| Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer | Advanced Breast Cancer With Ultra-Low HER2 Expression | Recruiting | Phase 2 | 2026-09-14 | NCT07817082 | |
| Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence | Neoplasms by Site, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, glucose metabolism disease, hyperglycemia, metabolic disease, neoplasm, skin disorder | Recruiting | Not stated | 2026-09-14 | NCT07817056 | |
| HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Recruiting | Not applicable | 2026-09-11 | NCT07786493 | |
| Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2026-09-10 | NCT06576921 | |
| Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Bilsky Grade 1c-3 | Spinal Metastases; Stereotactic Body Radiation Therapy (SBRT) | Recruiting | Not applicable | 2026-09-09 | NCT07809672 | |
| Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-09-03 | NCT07802288 | |
| Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-09-03 | NCT07801287 | |
| Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal Metastases | Spinal Cord Compression, central nervous system disorder, injury, nervous system disorder, spinal cord disorder, spinal cord injury | Recruiting | Not stated | 2026-09-03 | NCT07801274 | |
| IRE After Chemotherapy for Locally Advanced Pancreatic Cancer | IRE | Recruiting | Not applicable | 2026-09-02 | NCT07799935 |